A Multi-institutional Phase 2 Study of Imatinib Mesylate and Gemcitabine for First-Line Treatment of Advanced Pancreatic Cancer

BACKGROUND: The pancreatic tumor microenvironment is rich in receptors for platelet-derived growth factor (PDGFRs). Imatinib mesylate (IM) inhibits PDGFRs and decreases tumor interstitial fluid pressure, potentially improving drug access. These data and promising results in a phase 1 trial formed th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Moss, Rebecca A., Moore, Dirk, Mulcahy, Mary F., Nahum, Kenneth, Saraiya, Biren, Eddy, Simantini, Kleber, Martin, Poplin, Elizabeth A.
Format: Artigo
Sprache:Inglês
Veröffentlicht: International Society of Gastrointestinal Oncology 2012
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3415717/
https://ncbi.nlm.nih.gov/pubmed/22888387
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge